Literature DB >> 15538997

Relationship of acute mania symptomatology to maintenance treatment response.

Charles L Bowden1.   

Abstract

Most treatment of bipolar disorders addresses maintenance objectives. In the past 4 years, several large, blinded, randomized, placebo-controlled maintenance studies involving more than 3000 patients with bipolar I illness have been published, with analyses of background, symptomatic, and acute treatment factors contributing to maintenance effectiveness. This article summarizes these findings. Generally, indices of greater severity predict lower response rates to most monotherapy treatments. Some findings have been unexpected. Mixed mania did not predict different maintenance response to divalproex or lithium but predicted more side effects with either drug, and reduced efficacy of olanzapine or lamotrigine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538997     DOI: 10.1007/s11920-004-0013-0

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  20 in total

1.  Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium.

Authors:  M B Keller; P W Lavori; J M Kane; A J Gelenberg; J F Rosenbaum; E A Walzer; L A Baker
Journal:  Arch Gen Psychiatry       Date:  1992-05

Review 2.  Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.

Authors:  Trisha Suppes; Ellen B Dennehy; Alan C Swann; Charles L Bowden; Joseph R Calabrese; Robert M A Hirschfeld; Paul E Keck; Gary S Sachs; M Lynn Crismon; Marcia G Toprac; Steven P Shon
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

3.  Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.

Authors:  Lori Altshuler; Trisha Suppes; David Black; Willem A Nolen; Paul E Keck; Mark A Frye; Susan McElroy; Ralph Kupka; Heinz Grunze; Jörg Walden; Gabrielle Leverich; Kirk Denicoff; David Luckenbaugh; Robert Post
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

4.  Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy.

Authors:  Paul E Keck; Charles L Bowden; Jane M Meinhold; Laszlo Gyulai; Thomas J Prihoda; Jeffrey D Baker; Patricia J Wozniak
Journal:  Int J Psychiatry Clin Pract       Date:  2005       Impact factor: 1.812

5.  Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.

Authors:  F M Jacobsen
Journal:  J Clin Psychiatry       Date:  1993-06       Impact factor: 4.384

6.  A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.

Authors:  Francesco Colom; Eduard Vieta; Anabel Martinez-Aran; Maria Reinares; Jose Manuel Goikolea; Antonio Benabarre; Carla Torrent; Merce Comes; Barbara Corbella; Gemma Parramon; Josep Corominas
Journal:  Arch Gen Psychiatry       Date:  2003-04

7.  A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

Authors:  Guy M Goodwin; Charles L Bowden; Joseph R Calabrese; Heinz Grunze; Siegfried Kasper; Robin White; Paul Greene; Robert Leadbetter
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

8.  The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary.

Authors:  Guy M Goodwin; Allan H Young
Journal:  J Psychopharmacol       Date:  2003-12       Impact factor: 4.153

9.  An open-label trial of divalproex in children and adolescents with bipolar disorder.

Authors:  Karen Dineen Wagner; Elizabeth B Weller; Gabrielle A Carlson; Gary Sachs; Joseph Biederman; Jean A Frazier; Patricia Wozniak; Katherine Tracy; Ronald A Weller; Charles Bowden
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-10       Impact factor: 8.829

10.  Relapse and impairment in bipolar disorder.

Authors:  M J Gitlin; J Swendsen; T L Heller; C Hammen
Journal:  Am J Psychiatry       Date:  1995-11       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.